SBI Securities’s Tonix Pharmaceuticals TNXP Stock Holding History

SBI Securities’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$838	Sell	86 -4	-4%	-$47	﹤0.01%	2920
2026 Q2	$1.15K	Buy	90 +1	+1%	+$13	﹤0.01%	2758
2026 Q1	$1.22K	Buy	89 +13	+17%	+$200	﹤0.01%	2581
2025 Q4	$1.19K	Sell	76 -120	-61%	-$2.21K	﹤0.01%	2584
2025 Q3	$4.74K	Buy	196 +39	+25%	+$1.45K	﹤0.01%	2068
2025 Q2	$5.65K	Sell	157 -112	-42%	-$2.94K	﹤0.01%	1929
2025 Q1	$4.81K	Buy	269 +231	+608%	+$4.68K	﹤0.01%	1918
2024 Q4	$1.24K	Buy	+38	New	+$790	﹤0.01%	2512

Other funds holding TNXP

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Acorn Wealth Advisors Grand Blanc, Michigan $407M AUM 14.44% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CNBT

Cornerstone National Bank & Trust Palatine, Illinois $309M AUM 7.69% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

SBI Securities's TNXP Position: Q3 2026 in Review

SBI Securities reduced its Tonix Pharmaceuticals (TNXP) stake by 4.4% in Q3 2026, selling an estimated $47 and leaving 86 shares worth $838. The position accounts for ﹤0.01% of the portfolio, ranked #2920.

SBI Securities first reported a position in TNXP in Q4 2024 and has held it in 8 quarters since. The position peaked at $5.65K in Q2 2025. 20 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

SBI Securities held 86 shares of Tonix Pharmaceuticals worth $838 as of Q3 2026.
SBI Securities sold 4 Tonix Pharmaceuticals shares in Q3 2026, an estimated $47.
Tonix Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2920 holding.
SBI Securities first reported a position in Tonix Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Tonix Pharmaceuticals position peaked at $5.65K in Q2 2025.
20 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.